Diebold Nixdorf, Incorporated (DBD) — Fair Value Analysis

Base-case fair value (P50): $82.70 · Current price: $69.70 · Verdict: Undervalued

The Verdict on DBD

Our Monte Carlo simulations indicate that DIEBOLD NIXDORF INC (DBD) is currently Fairly Valued. With a median fair value (P50) of $82.70, DBD's current price of $69.70 suggests an +18.7% potential based on thousands of forward-looking scenarios. This assessment reflects a robust quantitative analysis, anchoring on DBD's specific operational and financial characteristics to project its most probable intrinsic value. The simulation, designed to capture a wide range of market and company-specific variables, positions $69.70 squarely within the expected range, mitigating concerns of immediate overvaluation.

How DBD stacks up against peers

DBD's operational and financial health is rated as average when compared against its sector. This quality tier implies that while DBD is not exhibiting significant distress, it also isn't demonstrating exceptional outperformance relative to its industry landscape. The Monte Carlo analysis incorporates this average quality tier into its valuation framework, influencing the fair value distribution and the likelihood of different outcomes. While a sector is not specified, this average standing reflects a balanced risk-reward profile embedded in the $82.70 fair value, suggesting that $69.70 appropriately discounts its current operational efficiency.

What this means for investors

Investors considering DBD at its current price of $69.70 should acknowledge its "Fairly Valued" verdict. The $82.70 fair value of $82.70, indicating +18.7% potential, suggests that current market pricing accurately reflects the company's fundamentals and future prospects as modeled. While there is an +18.7% gap to our median fair value, it's important to understand this is the central tendency of a wide distribution. FairCurve's simulations provide this granular insight, allowing for a clearer understanding of DBD's valuation dynamics. To gain a complete understanding of DBD's potential downside and upside scenarios, including the full bear-case (P10) and bull-case (P90) distribution, sign up for a free FairCurve account and track DBD's fair value as new fundamentals are released.